苯磺酸瑞马唑仑与右美托咪定用于ICU机械通气患者镇静:多中心、单盲、随机、非劣效性试验
这项多中心、单盲、随机、非劣效性试验纳入中国15个ICU的314例接受气管插管机械通气、预期需镇静8-48小时的成人患者,1:1随机接受苯磺酸瑞马唑仑或右美托咪定,均联合瑞芬太尼持续静脉输注镇痛,目标Richmond躁动-镇静评分-2至+1。符合方案集(PPS)中两组镇静有效率分别为82.6%和83.2%,意向治疗集(ITT)中均为72.9%,组间差异双侧95%CI下限分别为-3.0%和-2.6%,均高于预设10%非劣效界值。右美托咪定组心动过缓发生率高于瑞马唑仑组(4.7% vs 0.7%,p=0.029),其余次要终点和不良事件无组间差异。
要点
- 在预期需镇静8-48小时的机械通气成人中,苯磺酸瑞马唑仑镇静有效率不劣于右美托咪定(PPS 82.6% vs 83.2%,ITT均72.9%)。
- 非劣效界值设为10%,PPS和ITT集组间差异双侧95%CI下限分别为-3.0%和-2.6%,均未超过界值。
- 右美托咪定组心动过缓发生率高于瑞马唑仑组(4.7% vs 0.7%,p=0.029)。
- 两组其余次要终点和不良事件无组间差异。
- 镇静方案:瑞芬太尼1.2-9.0 µg/kg/hr持续静脉输注镇痛,目标RASS -2至+1。
适用人群与场景
- 中国15个ICU中接受气管插管机械通气、预期需镇静8-48小时的成人患者。
诊断标准与关键阈值
- 目标镇静范围为Richmond躁动-镇静评分(RASS)-2至+1。
- 非劣效界值设为10%。
处置流程与药物剂量
- 镇痛:瑞芬太尼持续静脉输注1.2-9.0 µg/kg/hr。
- 苯磺酸瑞马唑仑组:静脉给予初始负荷剂量0.1 mg/kg,随后维持剂量0.10-0.30 mg/kg/hr,以达到目标RASS -2至+1。
- 右美托咪定组:静脉给予初始负荷剂量0.20 µg/kg,随后维持剂量0.2-0.70 µg/kg/hr,以达到目标RASS -2至+1。
研究设计与关键结果
- 研究类型:多中心、单盲、随机、非劣效性试验;样本量314例(299例完成研究);中国15个ICU;2021年10月至2023年11月。
- 主要终点镇静有效率:PPS中苯磺酸瑞马唑仑组82.6% vs 右美托咪定组83.2%;ITT集中两组均为72.9%。
- 非劣效性:组间差异双侧95%CI下限在PPS为-3.0%,在ITT为-2.6%,均高于-10%界值。
- 次要终点:右美托咪定组心动过缓发生率高于苯磺酸瑞马唑仑组(4.7% vs 0.7%,p=0.029);其余次要终点和不良事件无组间差异。
证据类型、等级与局限
- 证据类型:多中心、单盲、随机、非劣效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于预期需镇静8-48小时的机械通气ICU成人患者,苯磺酸瑞马唑仑可作为右美托咪定的替代镇静选择,且心动过缓风险更低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate whether remimazolam besylate could provide noninferior sedation to dexmedetomidine in patients under mechanical ventilation (MV) in the ICU.
DESIGN: A multicenter, single-blind, randomized, noninferiority trial.
SETTING: Fifteen ICUs across China between October 2021 and November 2023.
PATIENTS: Adults under endotracheal intubation MV who were expected to require sedation for 8-48 hours.
INTERVENTIONS: Three hundred fourteen patients were randomly assigned at a 1:1 ratio to the remimazolam besylate or dexmedetomidine group. Analgesia was provided via a continuous IV infusion of remifentanil at 1.2-9.0 µg/kg/hr. Remimazolam besylate or dexmedetomidine was administered IV at an initial loading dose of 0.1 mg/kg followed by a maintenance dose of 0.10-0.30 mg/kg/hr or at an initial loading dose of 0.20 µg/kg followed by a maintenance dose of 0.2-0.70 µg/kg/hr to achieve the targeted sedation range on the Richmond Agitation-Sedation Scale of -2 to +1.
MEASUREMENTS AND MAIN RESULTS: Of the 314 patients enrolled, 299 completed the study. The sedation efficacy rates, as the primary endpoint, were 82.6% and 83.2% in remimazolam besylate and dexmedetomidine groups, respectively, in the per-protocol set (PPS), whereas the rate was 72.9% in both groups in the intention-to-treat (ITT) set. The noninferiority margin was set as 10%, and the lower limits of the two-sided 95% CI for the intergroup difference were -3.0% and -2.6% in the PPS and ITT sets, respectively. The dexmedetomidine group had a higher incidence of bradycardia than the remimazolam besylate group (4.7% vs. 0.7%; p = 0.029), whereas no intergroup differences were noted for the remaining secondary endpoints and adverse events.
CONCLUSIONS: Remimazolam besylate could provide noninferior sedation as dexmedetomidine with a lower risk of bradycardia for 48 hours in mechanically ventilated patients in the ICU.
参考来源
- Cheng W, Chen Y, He F, et al. Remimazolam Besylate Versus Dexmedetomidine As a Sedative in ICU Patients Undergoing Mechanical Ventilation: A Multicenter, Single-blinded, Randomized, Noninferiority Trial. Crit Care Med. 2026. PMID: 41524483. doi:10.1097/CCM.0000000000007011
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。